842 related articles for article (PubMed ID: 33937943)
1. Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention.
Perry TR; Roberts ML; Sunkara B; Maddula R; McLeish T; Gomez J; Lucas J; Rayan D; Patel S; Liang M; Bosnjak ZJ; Brown SA
Curr Oncol Rep; 2021 May; 23(7):77. PubMed ID: 33937943
[TBL] [Abstract][Full Text] [Related]
2. Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it?
Stack JP; Moslehi J; Sayed N; Wu JC
Eur Heart J; 2019 Jun; 40(22):1764-1770. PubMed ID: 29377985
[TBL] [Abstract][Full Text] [Related]
3. Pluripotent Stem Cell Modeling of Anticancer Therapy-Induced Cardiotoxicity.
Lyra-Leite DM; Burridge PW
Curr Cardiol Rep; 2020 Jun; 22(8):56. PubMed ID: 32562096
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in pluripotent stem cell-derived cardiac organoids and heart-on-chip applications for studying anti-cancer drug-induced cardiotoxicity.
Liu S; Fang C; Zhong C; Li J; Xiao Q
Cell Biol Toxicol; 2023 Dec; 39(6):2527-2549. PubMed ID: 37889357
[TBL] [Abstract][Full Text] [Related]
5. Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.
Sayed N; Ameen M; Wu JC
Cardiovasc Res; 2019 Apr; 115(5):949-959. PubMed ID: 30768178
[TBL] [Abstract][Full Text] [Related]
6. Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology.
Nair P; Prado M; Perea-Gil I; Karakikes I
Stem Cells Transl Med; 2019 Aug; 8(8):758-767. PubMed ID: 31020786
[TBL] [Abstract][Full Text] [Related]
7. hiPSCs in cardio-oncology: deciphering the genomics.
Pinheiro EA; Fetterman KA; Burridge PW
Cardiovasc Res; 2019 Apr; 115(5):935-948. PubMed ID: 30689737
[TBL] [Abstract][Full Text] [Related]
8. Cardio-oncology: management of cardiovascular toxicity.
Markman TM; Markman M
F1000Res; 2019; 8():. PubMed ID: 30755794
[TBL] [Abstract][Full Text] [Related]
9. Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey.
Jovenaux L; Cautela J; Resseguier N; Pibarot M; Taouqi M; Orabona M; Pinto J; Peyrol M; Barraud J; Laine M; Bonello L; Paganelli F; Barlesi F; Thuny F
Int J Cardiol; 2017 Aug; 241():387-392. PubMed ID: 28365180
[TBL] [Abstract][Full Text] [Related]
10. Interactions between cardiology and oncology drugs in precision cardio-oncology.
Kamaraju S; Mohan M; Zaharova S; Wallace B; McGraw J; Lokken J; Tierney J; Weil E; Fatunde O; Brown SA
Clin Sci (Lond); 2021 Jun; 135(11):1333-1351. PubMed ID: 34076246
[TBL] [Abstract][Full Text] [Related]
11. Cardio-oncology: the new frontier of clinical and preventive cardiology.
Paris S; Tarantini L; Navazio A; Faggiano P
Monaldi Arch Chest Dis; 2020 Jun; 90(2):. PubMed ID: 32571000
[TBL] [Abstract][Full Text] [Related]
12. The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology.
Fatunde OA; Brown SA
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963461
[TBL] [Abstract][Full Text] [Related]
13. Cellular model systems to study cardiovascular injury from chemotherapy.
Fonoudi H; Burridge PW
J Thromb Thrombolysis; 2021 May; 51(4):890-896. PubMed ID: 33051807
[TBL] [Abstract][Full Text] [Related]
14. Strategies to Prevent Cardiotoxicity.
Graffagnino J; Kondapalli L; Arora G; Hawi R; Lenneman CG
Curr Treat Options Oncol; 2020 Apr; 21(4):32. PubMed ID: 32270293
[TBL] [Abstract][Full Text] [Related]
15. [The Cardio-Oncology Guideline - A Comprehensive Approach to Managing Cardiovascular Risks in Cancer Patients].
Romann SW; Frey N; Lehmann L
Dtsch Med Wochenschr; 2024 Jun; 149(12):719-723. PubMed ID: 38781996
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological foundations of cardio-oncology.
Minotti G; Salvatorelli E; Menna P
J Pharmacol Exp Ther; 2010 Jul; 334(1):2-8. PubMed ID: 20335321
[TBL] [Abstract][Full Text] [Related]
17. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
[TBL] [Abstract][Full Text] [Related]
18. Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology.
Liang Z; He Y; Hu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142538
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
[TBL] [Abstract][Full Text] [Related]
20. Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro.
Matsa E; Burridge PW; Yu KH; Ahrens JH; Termglinchan V; Wu H; Liu C; Shukla P; Sayed N; Churko JM; Shao N; Woo NA; Chao AS; Gold JD; Karakikes I; Snyder MP; Wu JC
Cell Stem Cell; 2016 Sep; 19(3):311-25. PubMed ID: 27545504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
